Gritstone bio, Inc.

GRTS

US39868T1051

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 01:30:00 25/05/2024 am IST			5-day change	1st Jan Change
0.8016 ^USD	-2.52%		+1.80%	-60.71%

24/05	B. Riley Cuts Price Target on Gritstone bio to $3 From $6, Keeps Buy Rating	MT
09/05	Earnings Flash (GRTS) GRITSTONE BIO Posts Q1 Revenue $1.74M, vs. Street Est of $2.85M	MT

Gritstone Oncology, Inc. Announces the Addition of Jean-Charles Soria, to Its Scientific Advisory Board

June 10, 2020 at 05:30 pm IST

Gritstone Oncology, Inc. announced that Jean-Charles Soria, M.D., Ph.D., chief executive officer of Gustave Roussy Cancer Center, has joined the company’s scientific advisory board (SAB).

Latest news about Gritstone bio, Inc.

B. Riley Cuts Price Target on Gritstone bio to $3 From $6, Keeps Buy Rating	24/05	MT
Earnings Flash (GRTS) GRITSTONE BIO Posts Q1 Revenue $1.74M, vs. Street Est of $2.85M	10/05	MT
Transcript : Gritstone bio, Inc., Q1 2024 Earnings Call, May 09, 2024	10/05
Gritstone bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	10/05	CI
Gritstone Bio, Inc. Highlights the Durability and Potential Broad Utility of its Self-amplifying mRNA Vaccine at ESCMID Global 2024	30/04	CI
Gritstone Bio, Inc. Announces Board Changes	29/04	CI
Nature Medicine Publishes Interim Results from Gritstone Bio's Phase 1/2 Study of "Off-The-Shelf" Neoantigen Vaccine Platform	15/04	CI
Top Midday Decliners	02/04	MT
Gritstone bio Prices $32.5 Million Public Offering of Stock, Warrants	02/04	MT
Gritstone Bio Discloses Preliminary Progression-Free Survival Data From Colorectal Cancer Vaccine Trial; Shares Fall	02/04	MT
Gritstone Bio Starts Public Offering; Shares Drop After-Hours	02/04	MT
Gritstone Bio, Inc. Announces Positive Preliminary Progression-Free Survival and Long-Term Circulating Tumor DNA Data from Phase 2/3 Study of its Personalized Cancer Vaccine, Granite, Granite, Granite	02/04	CI
Earnings Flash (GRTS) GRITSTONE BIO Posts Q4 Revenue $16.3M	06/03	MT
Gritstone bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	06/03	CI
Gritstone Bio Announces Update to Comparative Phase 2B Covid-19 Clinical Trial	12/02	CI
Gritstone bio, Inc.(NasdaqGS:GRTS) dropped from NASDAQ Biotechnology Index	15/12	CI
B. Riley Adjusts Gritstone bio's Price Target to $6 From $8, Keeps Buy Rating	07/12	MT
Transcript : Gritstone bio, Inc. Presents at First Annual Goldman Sachs Catalyst Clinic, Dec-05-2023 11:00 AM	05/12
Earnings Flash (GRTS) GRITSTONE BIO Posts Q3 Revenue $1.6M	09/11	MT
Gritstone bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11	CI
Gritstone Bio, Inc. Announces Presentation of Results from Three Ongoing Phase 1 Studies Evaluating Its Self-Amplifying Mrna Vaccine Candidates Against Covid-19 (Part of the Company?s Coral Program) at IDWeek 2023	11/23/11	CI
Gritstone bio Offers Stock Options to Three New Employees	10/23/10	MT
Investors Await GDP, Jobless Claims as US Futures Trend Lower in Thursday's Premarket	28/23/28	MT
Piper Sandler Lifts Price Target on Gritstone bio to $7 From $6, Keeps Overweight Rating	28/23/28	MT
Gritstone Bio Gets Contract For Comparative COVID-19 Trial; Shares Jump After-Hours	28/23/28	MT

Gritstone bio, Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers next generation cancer and infectious disease immunotherapy candidates. It has developed two vectors that it deploys with the aim of eliciting the desired immune response: self-amplifying mRNA (samRNA) and chimpanzee adenovirus (ChAd). Its two oncology programs in clinical-stage development are GRANITE, individualized neoantigen-based immunotherapy, and SLATE, an off-the-shelf shared neoantigen-based immunotherapy. It has an infectious disease pipeline, which includes two programs in clinical-stage development: CORAL, a second-generation COVID-19 vaccine program that may have pan-coronavirus potential to protect against future coronavirus pandemics, and an HIV therapeutic/cure vaccine candidate. In oncology, it develops personalized vaccines that aim to destroy tumors through CD8+ (killer) T cell recognition of tumor cells by virtue of their surface display of neoantigens.

Sector

Pharmaceuticals

Calendar

17/06/2024 - Annual General Meeting

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Gritstone bio, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.8016 USD

Average target price

4.333 USD

Spread / Average Target

+440.59%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
GRITSTONE BIO, INC.	-60.71%	89.28M
CSL LIMITED	-2.00%	90.27B
SAMSUNG BIOLOGICS CO.,LTD.	-1.18%	40.12B
BIOGEN INC.	-15.83%	31.75B
UCB	+62.86%	26.6B
BIOMARIN PHARMACEUTICAL INC.	-21.68%	14.41B
INCYTE CORPORATION	-8.73%	12.92B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-15.05%	11.44B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-45.69%	11.3B
SWEDISH ORPHAN BIOVITRUM AB	+4.94%	8.87B

Biopharmaceuticals

Gritstone bio, Inc.

Equities

GRTS

US39868T1051

Pharmaceuticals

Gritstone Oncology, Inc. Announces the Addition of Jean-Charles Soria, to Its Scientific Advisory Board

Latest news about Gritstone bio, Inc.

Chart Gritstone bio, Inc.

Company Profile

Income Statement Evolution

Ratings for Gritstone bio, Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Biopharmaceuticals